Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer survival; however, rates have improved in the last 5 years regardless.

The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with ...

Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained.

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...

The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve ...

The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...